Biotech RadarJobs updated

COMPANY

Krystal Biotech

HQ: Pittsburgh, PA source · krystalbio.com ↗

FDA-approved therapeutic company Clinical Phase 3

11 open jobs · last seen Oct 23, 2026 · 19 sources

Keywords: gene therapy Dystrophic Epidermolysis Bullosa DEB - Dystrophic Epidermolysis Bullosa Recessive Dystrophic Epidermolysis Bullosa Dominant Dystrophic Epidermolysis Bullosa Cystic Fibrosis Hailey Hailey Disease Skin Diseases Lesion Skin Neurotrophic Keratitis Non-small Cell Lung Cancer Lung Cancer Metastatic Lung Cancer (NSCLC) Alpha 1-Antitrypsin Deficiency Epidermolysis Bullosa Dystrophica Recessive Epidermolysis Bullosa Dystrophica Epidermolysis Bullosa Dystrophica Dominans Melanoma Stage III Melanoma Stage IV Cutaneous Melanoma Wrinkles in Decolletage Pigmentation Décolleté Wrinkles Skin Roughness Wrinkle Fine Lines Skin Thickness Autosomal Recessive Ichthyosis TGM-1 Related Autosomal Recessive Congenital Ichthyosis KB407 (Nebulization) KB707 KB105 KB111 KB803 KB801 KB408 (Nebulization) KB304 KB301

Location: Pittsburgh, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

11Open jobs18Trials (company is sponsor)1FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Patient Access LiaisonRemoteNot statedOct 21, 2026
Regional Gene Therapy Liaison - South Midwest (TX/OK/MO/AR/KS)RemoteNot statedOct 21, 2026
Quality Assurance AssociateMoon Township, PANot statedOct 20, 2026
Quality Assurance AssociatePittsburgh, PANot statedOct 17, 2026
Biotech Warehouse / Materials AssociateMoon Township, PANot statedOct 15, 2026

See all 11 jobs

Timeline

  1. Trial start Early phase 1: A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease source ↗
  2. FDA FDA CBER noteworthy supplement: VYJUVEK (beremagene geperpavec-svdt) — BLA125774/89, Sep 12, 2025. Applicant at approval: Krystal Biotech, Inc. source ↗
  3. Trial start Phase 1/Phase 2: A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis source ↗
  4. Trial start Phase 3: A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa source ↗
  5. Trial start Phase 1/Phase 2: A Study Assessing KB304 for the Treatment of Wrinkles in Women source ↗
  6. Trial start —: A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB) source ↗
  7. Trial start Phase 1/Phase 2: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs source ↗
  8. Trial start Phase 1: A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency source ↗
  9. Trial start Phase 1/Phase 2: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors source ↗
  10. Trial start Phase 1: A Study Assessing KB407 for the Treatment of Cystic Fibrosis source ↗
  11. Trial start Phase 2: Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) source ↗
  12. Trial start Phase 1: A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis source ↗
  13. Trial start Phase 3: A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa source ↗
  14. Trial start —: Long-Term Follow-up Protocol source ↗
  15. Trial start I: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions source ↗
  16. Trial start Phase 3: Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB source ↗
  17. Trial start —: The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB) source ↗
  18. Trial start Phase 1/Phase 2: Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) source ↗
  19. Trial start I: A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 18

RecordTitlePhaseStatusStartPrimary completion
NCT07717346A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey DiseaseEarly phase 1RecruitingMay 6, 20262026-11 (estimated)
NCT05504837A Study Assessing KB407 for the Treatment of Cystic FibrosisPhase 1RecruitingJun 30, 20232026-12 (estimated)
NCT07016750A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaPhase 3RecruitingJun 20, 20252026-12 (estimated)
NCT06999733A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic KeratitisPhase 1/Phase 2RecruitingJul 7, 20252026-12 (estimated)
NCT06228326A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsPhase 1/Phase 2RecruitingApr 17, 20242027-02 (estimated)
NCT06049082A Study of KB408 for the Treatment of Alpha-1 Antitrypsin DeficiencyPhase 1RecruitingFeb 15, 20242025-12 (estimated)
NCT06563414A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)Not listedRecruitingAug 2, 20242025-12 (estimated)
NCT05970497A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsPhase 1/Phase 2RecruitingOct 31, 20232027-07 (estimated)
NCT06724900A Study Assessing KB304 for the Treatment of Wrinkles in WomenPhase 1/Phase 2Active, not recruitingNov 20, 20242025-07 (estimated)
NCT04540900A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin DepressionsIActive, not recruitingOct 7, 2020Oct 16, 2024 (actual)
NCT04917874A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaPhase 3CompletedMay 25, 2021Jul 31, 2023 (actual)
NCT05095246A Study of Inhaled KB407 for the Treatment of Cystic FibrosisPhase 1WithdrawnMar 8, 2022Jul 1, 2024 (estimated)
NCT05735158Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)Phase 2Unknown status (ClinicalTrials.gov)2023-032024-03 (estimated)
NCT04491604Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEBPhase 3CompletedAug 17, 2020Oct 29, 2021 (actual)
NCT03536143A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB PatientsICompletedMay 6, 2018Nov 1, 2019 (actual)
NCT04214002The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)Not listedWithdrawn2020-01Feb 24, 2020 (actual)
NCT04047732Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)Phase 1/Phase 2Unknown status (ClinicalTrials.gov)Aug 27, 20192022-10 (estimated)
NCT04917887Long-Term Follow-up ProtocolNot listedRecruitingMay 25, 2021May 25, 2028 (estimated)

FDA records (last 2 years)

Open jobs 11

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Patient Access LiaisonRemoteNot statedOct 21, 2026Not stated
Regional Gene Therapy Liaison - South Midwest (TX/OK/MO/AR/KS)RemoteNot statedOct 21, 2026Not stated
Quality Assurance AssociateMoon Township, PANot statedOct 20, 2026Not stated
Quality Assurance AssociatePittsburgh, PANot statedOct 17, 2026Not stated
Biotech Warehouse / Materials AssociateMoon Township, PANot statedOct 15, 2026Entry
Warehouse AssociatePittsburgh, PANot statedOct 15, 2026Entry
Senior BiostatisticianPittsburgh, PANot statedOct 11, 2026Senior
Validation (CSV) AssociatePittsburgh, PANot statedOct 11, 2026Entry
Quality Assurance Document Control AssociateMoon Township, PANot statedOct 11, 2026Entry
Quality Assurance Training CoordinatorPittsburgh, PANot statedOct 11, 2026Entry
Regional Gene Therapy Consultant - Pacific NorthwestRemoteNot statedOct 11, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Krystal Biotech on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback